EOLS Evolus Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: EOLS

Price (delayed)

$8

Market cap

$528.4M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.52

Enterprise value

$648.04M

?
Relative Growth: Rel. Growth: 78
Relative Strength: Rel. Strength: 84
Relative Valuation: Rel. Valuation: 22
Relative Profitability: Rel. Profitability: 35

Evolus is a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our ...

Highlights
The company's EPS rose by 46% YoY and by 22% QoQ
Evolus's net income has increased by 45% YoY and by 21% QoQ
Evolus's equity has shrunk by 66% YoY and by 7% QoQ
The quick ratio has declined by 37% year-on-year and by 27% since the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.evolus.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of EOLS

EOLS stock price

How has the Evolus stock price performed over time
Intraday
-3.03%
1 week
0.13%
1 month
-4.65%
1 year
29.24%
YTD
20.3%
QTD
15.27%

Financial performance

How have Evolus's revenue and profit performed over time
Revenue
$316.49M
Gross profit
$211.21M
Operating income
-$18.67M
Net income
-$34.33M
Gross margin
66.7%
Net margin
-10.8%
The company's operating margin has surged by 62% YoY and by 27% QoQ
The operating income has soared by 57% year-on-year and by 23% since the previous quarter
The net margin has surged by 52% year-on-year and by 25% since the previous quarter
Evolus's net income has increased by 45% YoY and by 21% QoQ

Price vs fundamentals

How does EOLS's price correlate with its fundamentals

Growth

What is Evolus's growth rate over time

Valuation

What is Evolus stock price valuation
P/E
N/A
P/B
N/A
P/S
1.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.05
The company's EPS rose by 46% YoY and by 22% QoQ
Evolus's equity has shrunk by 66% YoY and by 7% QoQ
The P/S is 41% less than the 5-year quarterly average of 2.9 but 32% more than the last 4 quarters average of 1.3
Evolus's revenue has increased by 14% YoY and by 4.9% QoQ

Efficiency

How efficient is Evolus business performance
The ROIC has soared by 65% YoY and by 26% from the previous quarter
The company's return on sales has surged by 62% YoY and by 29% QoQ
Evolus's ROA has increased by 45% YoY and by 23% from the previous quarter

Dividends

What is EOLS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EOLS.

Financial health

How did Evolus financials performed over time
The total assets is 11% less than the total liabilities
The quick ratio has declined by 37% year-on-year and by 27% since the previous quarter
The company's current ratio fell by 25% YoY and by 17% QoQ
Evolus's equity has shrunk by 66% YoY and by 7% QoQ
Evolus's debt to equity has increased by 36% YoY and by 7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.